CN118576586A - 治疗神经和精神疾病的方法 - Google Patents
治疗神经和精神疾病的方法 Download PDFInfo
- Publication number
- CN118576586A CN118576586A CN202410509785.9A CN202410509785A CN118576586A CN 118576586 A CN118576586 A CN 118576586A CN 202410509785 A CN202410509785 A CN 202410509785A CN 118576586 A CN118576586 A CN 118576586A
- Authority
- CN
- China
- Prior art keywords
- patient
- disorder
- compound
- pharmaceutically acceptable
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776247P | 2018-12-06 | 2018-12-06 | |
| US62/776,247 | 2018-12-06 | ||
| US201962829796P | 2019-04-05 | 2019-04-05 | |
| US62/829,796 | 2019-04-05 | ||
| CN201980087996.5A CN113271936A (zh) | 2018-12-06 | 2019-12-05 | 治疗神经和精神疾病的方法 |
| PCT/US2019/064646 WO2020118032A1 (en) | 2018-12-06 | 2019-12-05 | Methods of treating neurological and psychiatric disorders |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980087996.5A Division CN113271936A (zh) | 2018-12-06 | 2019-12-05 | 治疗神经和精神疾病的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118576586A true CN118576586A (zh) | 2024-09-03 |
Family
ID=69024675
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410509785.9A Pending CN118576586A (zh) | 2018-12-06 | 2019-12-05 | 治疗神经和精神疾病的方法 |
| CN201980087996.5A Pending CN113271936A (zh) | 2018-12-06 | 2019-12-05 | 治疗神经和精神疾病的方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980087996.5A Pending CN113271936A (zh) | 2018-12-06 | 2019-12-05 | 治疗神经和精神疾病的方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20200179336A1 (enExample) |
| EP (1) | EP3890726A1 (enExample) |
| JP (2) | JP2022511509A (enExample) |
| KR (1) | KR20210100667A (enExample) |
| CN (2) | CN118576586A (enExample) |
| AU (2) | AU2019394956B2 (enExample) |
| CA (1) | CA3122261A1 (enExample) |
| MX (1) | MX2021006553A (enExample) |
| WO (1) | WO2020118032A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104193761B (zh) | 2009-12-04 | 2017-10-17 | 桑诺维恩药品公司 | 多环化合物及其使用方法 |
| BR112019001407A2 (pt) | 2016-07-29 | 2019-07-09 | Sunovion Pharmaceuticals Inc. | compostos e composições e usos dos mesmos |
| EP3582815A1 (en) | 2017-02-16 | 2019-12-25 | Sunovion Pharmaceuticals Inc. | Methods of treating schizophrenia |
| MX2020000523A (es) | 2017-08-02 | 2020-08-20 | Sunovion Pharmaceuticals Inc | Compuestos de isocromano y usos de los mismos. |
| SG11202007823PA (en) | 2018-02-16 | 2020-09-29 | Sunovion Pharmaceuticals Inc | Salts, crystal forms, and production methods thereof |
| KR20230003503A (ko) | 2020-04-14 | 2023-01-06 | 선오비온 파마슈티컬스 인코포레이티드 | 신경학적 및 정신의학적 장애의 치료를 위한 (S)-(4,5-디히드로-7H-티에노[2,3-c]피란-7-일)-N-메틸메탄아민 |
| US20220165391A1 (en) * | 2020-11-25 | 2022-05-26 | Kyndryl, Inc. | Multi-stage treatment recommendations |
| KR20240110935A (ko) * | 2021-09-23 | 2024-07-16 | 스미토모 파마 아메리카, 인크. | 대사 장애를 치료하는 방법 |
| CA3260160A1 (en) | 2022-08-30 | 2024-03-07 | Sumitomo Pharma America, Inc. | ULOTARONT FOR THE ADJUVANT TREATMENT OF MAJOR DEPRESSIVE DISORDER |
| AU2023358704A1 (en) | 2022-10-13 | 2025-05-29 | Sumitomo Pharma America, Inc. | Methods of reducing physical dependence to neuropsychiatric treatments |
| WO2024092070A1 (en) * | 2022-10-28 | 2024-05-02 | Sumitomo Pharma America, Inc. | Ulotaront for treating anxiety and associated conditions |
| CN120187422A (zh) | 2022-11-15 | 2025-06-20 | 住友制药美国公司 | 使用ulotaront转换神经精神病学药物的方法 |
| CN115754079B (zh) * | 2022-11-28 | 2025-04-04 | 合肥和合医疗科技有限公司 | 一种同时检测7种精神药物及其代谢产物含量的方法 |
| CN117594119B (zh) * | 2024-01-17 | 2024-05-10 | 北京大学第六医院 | 用于预测帕罗西汀或其药用盐对抑郁或焦虑症患者疗效的装置 |
| WO2025252814A1 (en) | 2024-06-04 | 2025-12-11 | Duc Duy Vo | Methods for treating trace amine-associated receptor 1 (taar1)-associated diseases or disorders comprising administration of novel taar1 agonists or pharmaceutical compositions thereof |
| WO2026015878A1 (en) * | 2024-07-12 | 2026-01-15 | Mindx Therapeutics, Inc. | A new combination therapy for treatment-resistant depression in patients with co-morbid metabolic syndrome |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104193761B (zh) | 2009-12-04 | 2017-10-17 | 桑诺维恩药品公司 | 多环化合物及其使用方法 |
| EP3582815A1 (en) * | 2017-02-16 | 2019-12-25 | Sunovion Pharmaceuticals Inc. | Methods of treating schizophrenia |
| SG11202007823PA (en) | 2018-02-16 | 2020-09-29 | Sunovion Pharmaceuticals Inc | Salts, crystal forms, and production methods thereof |
| WO2019161236A1 (en) * | 2018-02-16 | 2019-08-22 | Sunovion Pharmaceuticals Inc. | Methods of treating social function disorders |
-
2019
- 2019-12-05 CN CN202410509785.9A patent/CN118576586A/zh active Pending
- 2019-12-05 KR KR1020217020606A patent/KR20210100667A/ko not_active Ceased
- 2019-12-05 JP JP2021531942A patent/JP2022511509A/ja active Pending
- 2019-12-05 CN CN201980087996.5A patent/CN113271936A/zh active Pending
- 2019-12-05 MX MX2021006553A patent/MX2021006553A/es unknown
- 2019-12-05 CA CA3122261A patent/CA3122261A1/en active Pending
- 2019-12-05 WO PCT/US2019/064646 patent/WO2020118032A1/en not_active Ceased
- 2019-12-05 AU AU2019394956A patent/AU2019394956B2/en active Active
- 2019-12-05 US US16/704,202 patent/US20200179336A1/en not_active Abandoned
- 2019-12-05 EP EP19828449.9A patent/EP3890726A1/en active Pending
-
2024
- 2024-02-01 US US18/429,524 patent/US20240350453A1/en not_active Abandoned
- 2024-11-15 JP JP2024199397A patent/JP2025024102A/ja active Pending
-
2025
- 2025-01-08 US US19/013,028 patent/US20250312308A1/en active Pending
- 2025-08-06 AU AU2025213591A patent/AU2025213591A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3122261A1 (en) | 2020-06-11 |
| AU2019394956B2 (en) | 2025-05-08 |
| KR20210100667A (ko) | 2021-08-17 |
| MX2021006553A (es) | 2021-09-08 |
| US20240350453A1 (en) | 2024-10-24 |
| AU2025213591A1 (en) | 2025-08-21 |
| JP2025024102A (ja) | 2025-02-19 |
| JP2022511509A (ja) | 2022-01-31 |
| US20200179336A1 (en) | 2020-06-11 |
| CN113271936A (zh) | 2021-08-17 |
| US20250312308A1 (en) | 2025-10-09 |
| AU2019394956A1 (en) | 2021-06-17 |
| WO2020118032A1 (en) | 2020-06-11 |
| EP3890726A1 (en) | 2021-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240350453A1 (en) | Methods of treating neurological and psychiatric disorders | |
| EP4135690B1 (en) | (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating, preventing and/or managing a neurological and/or psychiatric disorder | |
| CN114340670B (zh) | T-型钙通道调节剂的制剂及其使用方法 | |
| JP2022105159A (ja) | 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン | |
| CA2884260A1 (en) | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease | |
| CN115776894A (zh) | T型钙通道调节剂的使用方法 | |
| US20250295646A1 (en) | Methods of use of t-type calcium channel modulators | |
| JP2009500425A (ja) | エスゾピクロン及びトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−ｎ−メチル−１−ナフタレンアミン又はトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法 | |
| JP5553955B2 (ja) | 鬱病の処置のための蘇生薬モダフィニルおよび抗鬱薬の組み合わせ | |
| HK40057761A (en) | Methods of treating neurological and psychiatric disorders | |
| TW200534848A (en) | 1-[2h-1-benzopyran-2-one-8-yl]-piperazine derivatives for the treatment of movement disorders | |
| WO2017151006A1 (ru) | Фармацевтическая композиция для лечения функциональных психических расстройств | |
| HK40064212A (en) | Modified release formulations and uses thereof | |
| HK40000275A (en) | Compounds having melatonin receptor affinity as prophylactic or therapeutic agent for delirium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |